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Migraine is a prevalent neurological disease that is characterized by unpredictable
episodic attacks of intense head pain. The underlying pathology involves sensitization
and activation of the trigeminal system. Although non-invasive vagus nerve stimulation
(nVNS) is recommended for the treatment of migraine, the abortive mechanism of action
is not well-understood. The goal of this study was to compare the ability of nVNS and
sumatriptan to inhibit trigeminal activation in two animal models of episodic migraine and
to investigate the receptor mechanism of action of nVNS. Nocifensive head withdrawal
response was investigated in adult male Sprague Dawley rats using von Frey filaments. To
induce trigeminal nociceptor sensitization, complete Freund’s adjuvant was injected in the
trapezius muscle and trigeminal neurons were activated by exposure to a pungent odor
or injection of the nitric oxide donor sodium nitroprusside. Some animals received nVNS
or sumatriptan as treatment. Some animals were injected intracisternally with antagonists
of GABAA , 5-HT3 or 5-HT7 receptors prior to nVNS since these receptors are implicated
in descending modulation. While unsensitized animals exposed to the pungent odor or
nitric oxide alone did not exhibit enhanced mechanical nociception, sensitized animals
with neck muscle inflammation displayed increased trigeminal nocifensive responses.
The enhanced nociceptive response to both stimuli was attenuated by nVNS and
sumatriptan. Administration of antagonists of GABAA , 5-HT3, and 5-HT7 receptors in the
upper spinal cord suppressed the anti-nocifensive effect of nVNS. Our findings suggest
that nVNS inhibits trigeminal activation to a similar degree as sumatriptan in episodic
migraine models via involvement of GABAergic and serotonergic signaling to enhance
central descending pain modulation.
Keywords: neck inflammation, pain, sensitization, sumatriptan, nitric oxide, vagus nerve
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HIGHLIGHTS

Migraineurs are genetically predisposed to development of
a hyperexcitable nervous system that is susceptible to multiple
risk factors, which function to promote peripheral and central
sensitization or can act as triggers to initiate a migraine attack
(15). Premonitory symptoms may include increased sensitivity
to physical stimuli such as flickering lights, loud, or irregular
sounds, or even pungent odors such as those from the California
bay laurel (CBL) or headache tree (16, 17). Similar to other
complex neurological diseases, stress and anxiety are reported
migraine risk factors that can significantly influence disease
onset, progression, and maintenance of the clinical phenotype
(18) and can manifest as increased tension and pain in neck and
shoulder muscles (19). Chronic muscle tension and inflammation
in the neck and shoulders can mediate persistent muscle fiber
contraction, local ischemia, and the release of pro-inflammatory
mediators that facilitate sensitization of primary and secondary
nociceptors (20). The convergence in the upper spinal cord of
nerves providing sensory innervation of neck/shoulder muscles
and those emanating from the trigeminal ganglion may explain
why neck/shoulder pathology is often cited as a risk factor
for orofacial pain conditions including migraine (21, 22). In
support of this notion, neck muscle inflammation has been
reported to promote sensitization of primary trigeminal neurons
so that exposure to a known migraine trigger, the pungent odor
from a CBL leaf extract, was sufficient to cause an increase in
trigeminal nociception in response to mechanical stimulation
(23). One of the main active molecules in CBL trees leaves
is umbellulone, which has been shown to cause activation
of TRPA1, the subsequent release of CGRP, and to increase
trigeminal nociception (17). Another factor known to promote
activation of trigeminal nociceptors in animal models of migraine
is nitric oxide (24). Using nitric oxide donors to mimic migraine
pathophysiology is supported by human data that infusion of a
nitric oxide donor in migraine susceptible individuals will trigger
a migraine attack (25). Thus, a goal of this study was to compare
the efficacy of nVNS to sumatriptan in two animal models of
episodic migraine involving trigeminal sensitization mediated by
neck muscle inflammation and trigeminal activation via either a
pungent odor or nitric oxide. Another goal was to investigate the
mechanism of action of nVNS to inhibit trigeminal nociception.

- Neck muscle inflammation mediated sensitization of the
trigeminal system to a pungent odor or nitric oxide that
promoted mechanical nociception.
- nVNS inhibited trigeminal nociception in two models of
episodic migraine.
- The inhibitory effects of nVNS involve GABAergic and
serotonergic pathways.

INTRODUCTION
Migraine is a prevalent neurological disease characterized by
unpredictable episodic attacks of severe head pain that is
accompanied by autonomic symptoms including photophobia,
phonophobia, and nausea (1). The disease burden of migraine
is significant since it disproportionally affects women of
childbearing age and negatively impacts performance at school
and work, and interferes with family and social activities (2–
4). Migraine pathology involves sensitization and activation of
the trigeminal system, which provides sensory innervation to
much of the head and face including the meninges (5). Recently,
non-invasive electrical stimulation of the vagus nerve has been
reported to be beneficial in the treatment of migraine and cluster
headache (6–9). The pathological pain associated with migraine
involves activation of trigeminal ganglion nerves, which provide
sensory innervation of the head and face and relay nociceptive
signals to the spinal trigeminal nucleus (STN) (10). The use of
a non-invasive vagus nerve stimulator (nVNS, gammaCoreTM ) is
FDA approved for the acute (episodic) and preventive (episodic
and chronic) treatment of cluster headache and the acute
treatment of migraine in adult patients. Additionally, results
from clinical trials have provided evidence that nVNS is a
safe and well-tolerated therapeutic option (6, 9). Importantly,
the reported 2-h pain-free rate for nVNS in treating episodic
migraine is similar to that of the triptans (11). Thus, nVNS is
proposed as a novel non-pharmacological therapeutic alternative
or complement to the triptan class of abortive migraine drugs.
Although similarly effective to triptans, nVNS likely functions
via different physiological and cellular mechanisms to modulate
pain signaling in response to trigeminal nerve activation. The
mechanism by which triptans function to block trigeminal pain
is thought to involve inhibiting the release of calcitonin-gene
related peptide (CGRP) and other pro-inflammatory molecules
from peripheral and central terminals of the trigeminal nerve as
well from the cell body within the ganglion (12). In contrast,
the inhibitory effect of nVNS as an acute migraine treatment
is proposed to promote multiple distinct cellular changes
and pathways within the brain and spinal cord to facilitate
descending pain modulation (13). The descending inhibitory
pathway is known to involve activation of 5-HT3 and 5-HT7
receptors on inhibitory interneurons that stimulates release of
glycine and GABA, which act as inhibitory neurotransmitters
of primary or secondary trigeminal nociceptors (14). Thus, the
reported efficacy of nVNS may involve modulation of GABAergic
and serotonergic signaling but this pathway has not been
demonstrated in episodic migraine models.
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METHODS
Animals
One hundred and ninety-five adult (d45-d56) Sprague Dawley
male rats (200–300 g), were purchased from Missouri State
University’s Central Management Breeding Colony (Springfield,
MO) and allowed to acclimate for 1 week to facility conditions
prior to use. Animals were housed individually in plastic rat cages
with aspen chip bedding and unrestricted access to both food and
water in a room with 12 h light/dark cycles. All protocols were
approved by Missouri State University’s Institutional Animal
Care and Use Committee and conducted in compliance with the
Animal Welfare Act, National Institutes of Health, and ARRIVE
Guidelines. Concerted efforts were made to minimize suffering,
as well as the number of animals. The attending veterinarian
provided guidance on appropriate dosing of all compounds and
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Nocifensive Behavior Testing

also determined if animals were to be removed from the study
due to excessive suffering. One hundred eighty-two animals were
used for final analysis, due to exclusion of outliers that were
defined as average values more than 2 standard deviations from
the mean of that group at one or more timepoints. No animals
were removed from the study due to ill health.

Behavioral changes were the primary outcome measured in
this study. Changes in nocifensive response to mechanical
stimulation of trigeminal neurons were determined essentially
as described (23). Prior to nociception testing, animals were
allowed to acclimate to the Durham Animal Holder (UGO Basile,
Gemonio, Italy) in the designated procedure room for 5 min on
3 consecutive days. To minimize reflexive or startle responses,
animals were conditioned to a mechanical stimulus by gently
rubbing the hair in the facial region with a pipette tip. This
method measures deep musculoskeletal pain responses rather
than cutaneous, reflexive defensive responses and hence higher
weight filaments were required to test nociception. Following
acclimations, animals were allowed to rest for 48 h prior to
baseline assessments.
Mechanical nocifensive thresholds were determined in
response to a series of calibrated von Frey filaments (Stoelting,
Wood Dale, IL) between 8 a.m. and 12 p.m. Nocifensive
withdrawal reactions, defined as a head withdrawal observed
prior to the bending of the filament, were verified by two
scientists blinded to the experimental conditions. Each filament
was applied 5 times over both the right and left areas of
each animal and reported as an average number of reactions.
Animals were randomly sorted into groups, and baseline
measurements were established prior to any treatments. Animals
that responded on average more than 2.5 times to the 100 g
filament during baseline measurements were not included in
the study. Additional measurements were taken 8 days postmuscle injections, 2 h post odor exposure or SNP injections, 1 h
post nVNS or sumatriptan treatments, and 24 h post treatment.
Animals were euthanized following testing via CO2 asphyxiation
and decapitation.

Sensitization and Activation of Trigeminal
Nociceptive Neurons
The experimental design for the first episodic migraine model
was based on a prior study and involves activation of sensitized
trigeminal neurons in response to exposure to a pungent odor
(23). Animals were placed under 3% isoflurane and received 10
injections of 10 µl of complete Freund’s adjuvant (CFA, SigmaAldrich, St. Louis, MO; 1:1 in 0.9% sterile saline) into the upper
trapezius. Animals were monitored for normal behaviors for a
total of 8 days. To cause activation of trigeminal nociceptors,
animals were exposed for 10 min to the volatile compounds from
an oil extract obtained from California bay laurel tree leaves
(CBL, World Spice, Seattle, WA) that was prepared as described
previously (23).
In the second episodic migraine model, nitric oxide was
used to mediate trigeminal nociceptor activation in sensitized
animals 8 days post trapezius CFA injection. Animals were lightly
anesthetized using 3% isoflurane and injected intraperitoneally
at a dose of 0.01 mg/kg with sodium nitroprusside (SNP, SigmaAldrich) dissolved in sterile 0.9% saline. This dose was chosen
since it did not cause increased nociception in naïve animals and
hence was determined to be subthreshold. In control animals, an
equal volume of sterile saline was injected.

nVNS and Sumatriptan Treatments
The procedure for nVNS was performed essentially as described
previously (23). Animals were lightly anesthetized under 3%
isoflurane and the stimulator electrodes placed on a shaved area
over the vagus nerve. Initially, a 1 ms pulse of 5 kHz sine waves,
repeated at 25 Hz, for 2 min was administered that was followed
5 min later by a second 2 min stimulation. Animals receiving
sumatriptan were given a dose of 0.3 mg/kg subcutaneously,
which was shown previously to effectively inhibit trigeminal
activation (26).

Statistical Design and Analysis
An a priori power analysis using G∗ Power Software (Dusseldorf,
Germany), allowing for comparison between groups at 5 time
points, resulted in a recommended minimum of 5 animals
per group to detect effects of treatments. Following collection,
data were evaluated for normality using a Shapiro–Wilk test.
Behavioral data were found to be non-normal (P < 0.05), so
non-parametric statistical tests were applied. To determine if
nociception was different across all groups, a Kruskal–Wallis
test was performed. Upon reaching a significant result, a Mann–
Whitney U-test with a Wilcoxon’s W post-hoc test was performed
to determine if there were pairwise differences in nociception
between groups at each evaluated time point. Statistical analysis
was performed using SPSS Statistical Software 24 (IBM), and
changes were considered significant if P < 0.05.

Inhibitor Injections
Animals were lightly anesthetized using 3% isoflurane prior to
intracisternal injection of antagonists to GABAA and the 5HT3 and 5-HT7 receptors. Bicuculline (GABAA inhibitor, Tocris
Bioscience, Minneapolis, MN) was dissolved in DMSO, then
diluted to 20 µM in sterile 0.9% saline, while Ondansetron
Hydrochloride (5-HT3 inhibitor, Tocris) and SB 269970 (5HT7 inhibitor, Tocris) were dissolved in 0.9% sterile saline to a
final concentration of 100 nM. In addition, a mixture of 100 nM
Ondansetron and 100 nM SB 269970 was prepared in sterile
saline. All inhibitors were administered via injection of 20 µl
between the occipital bone and C1 vertebrae to naïve animals or
delivered immediately prior to nVNS (2 h post odor exposure).
Bicuculline was also administered to sensitized animals that
received CBL exposure with no nVNS treatment.
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RESULTS
Initially, the level of trigeminal nociception to mechanical
stimulation was determined with the use of von Frey filaments
in a model of episodic migraine (Figure 1). The average number
of nocifensive head withdrawals to mechanical stimulation was
<1 response out of 5 applications at the basal time point for all
experimental conditions. At day 8, the nociceptive response for
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FIGURE 1 | nVNS and sumatriptan inhibit trigeminal nociception mediated by
a pungent odor in sensitized animals. The average nocifensive head
withdrawal response ±SEM of 5 applications to each side to mechanical
stimuli are reported. Some animals were left untreated (Naïve), some were
injected with saline in the trapezius (Saline) and exposed to the pungent
extract from California Bay Laurel leaves (CBL), while others were injected with
complete Freund’s adjuvant 8 days prior to exposure to CBL (M+CBL) and
nociceptive responses determined at 2 h, 3 h, and 1 day post CBL exposure.
Some of the M+CBL animals were treated with nVNS or sumatriptan and
nociception measured 1 h and 1 day post treatment. *P < 0.05 when
compared to Naïve while #P < 0.05 compared to M+CBL.

FIGURE 2 | nVNS and sumatriptan inhibit trigeminal nociception mediated by
nitric oxide in sensitized animals. The average nocifensive head withdrawal
response ±SEM of 5 applications to each side to mechanical stimuli are
reported. Some animals were left untreated (Naïve), some were injected with
saline in the trapezius (Saline) and exposed to the nitric oxide donor sodium
nitroprusside (SNP), while others were injected with complete Freund’s
adjuvant 8 days prior to exposure to SNP (M+SNP) and nociceptive
responses determined at 2 h, 3 h, and 1 day post SNP exposure. Some of the
M+SNP animals were treated with nVNS or sumatriptan and nociception
measured 1 h and 1 day post treatment. *P < 0.05 when compared to Naïve
while #P < 0.05 compared to M+SNP.

all conditions including animals that received upper trapezius
injection of CFA were similar to basal levels. In sensitized animals
mediated by neck muscle inflammation however (n = 8), the
average number of nocifensive responses was significantly (P <
0.05) elevated over naïve (n = 12) levels 2 h after exposure to the
pungent odor from a CBL extract (P < 0.001) but not in animals
injected with saline (n = 9) in the upper trapezius (P = 0.39). One
hour after treatment with nVNS (n = 7) or sumatriptan (n = 8)
(3 h after odor exposure) a significant decrease (P = 0.001, P =
0.028) in nociception was observed when compared to untreated
sensitized animals, which were still elevated at this time point (P
< 0.001). The average number of nocifensive responses was no
longer significantly different between any groups 1 day post odor
exposure or treatment with nVNS or sumatriptan (P = 0.071).
No change in nociception was observed in animals receiving only
saline at 3 h and day 1 (P = 0.62, P = 0.89).
The effect of nVNS and sumatriptan were also compared
in a second animal model of episodic migraine. In this model,
sensitization of trigeminal nociceptive neurons was mediated by
injection of CFA in the upper trapezius 8 days prior to injection
of the nitric oxide donor sodium nitroprusside (SNP), which was
used to trigger activation and a nocifensive response (Figure 2).
Consistent with the CBL data, in sensitized animals mediated by
neck muscle inflammation, the average number of nocifensive
responses was significantly (P < 0.05) elevated over naive levels
2 h after injection of SNP (n = 12, P < 0.001) but not in animals

injected with saline in the upper trapezius prior to SNP injection
(n = 6, P = 0.61). One hour after treatment with nVNS (3 h after
CBL) a significant decrease (n = 7, P < 0.001) in nociception
was observed when compared to untreated sensitized animals,
which were still significantly elevated over naive (P < 0.001).
Sumatriptan also caused a decrease in the average number of
withdrawal responses such that the response was not significantly
different from SNP-stimulated animals or naive levels (n = 8, P =
0.13, P = 0.15). The average number of nocifensive responses was
no longer significantly different between groups 1 day post SNP
or treatment with nVNS or sumatriptan (P = 0.15). No change in
nociception was observed in animals receiving only saline at 3 h
and day 1 (P = 0.89, P = 0.96).
To determine if intracisternal administration of inhibitors
of the GABAA , 5-HT3, and 5-HT7 receptors would cause a
change in the basal level of trigeminal nociception to mechanical
stimulation, unsensitized animals received injections of selective
antagonists and nocifensive responses were measured at the same
time points as the episodic migraine models. Administration
of the GABAA inhibitor Bicuculline (20 µM) or a mixture
of antagonists of 5-HT3 (Ondansetron, 100 nM) and 5-HT7
(SB-269970, 100 nM) did not mediate a significant difference
in the average number of nocifensive responses at any of
the time points (data not shown). To test if the inhibitory
effect of nVNS on trigeminal nociception observed in the
CBL odor-induced episodic migraine model involved GABAA
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FIGURE 3 | Inhibitory effect of nVNS on trigeminal nociception involves
GABAA . The average nocifensive head withdrawal response ±SEM of 5
applications to each side to mechanical stimuli are reported. Some animals
were left untreated (Naïve), some were injected with complete Freund’s
adjuvant 8 days prior to exposure to a pungent extract from California Bay
Laurel leaves (M+CBL) and nociceptive responses determined at 2 h, 3 h, and
1 day post CBL exposure. Some of the M+CBL animals were treated with
Bicuculline and/or nVNS 2 h after CBL exposure and nociception measured
1 h and 1 day post treatment. *P < 0.05 when compared to Naïve while #P <
0.05 compared to M+CBL.

FIGURE 4 | Anti-nociceptive effect of nVNS involves 5-HT3 and 5-HT7
receptors. The average nocifensive head withdrawal response ±SEM of 5
applications to each side to mechanical stimuli are reported. Some animals
were left untreated (Naïve), some were injected with complete Freund’s
adjuvant 8 days prior to exposure to a pungent extract from California Bay
Laurel leaves (M+CBL) and nociceptive responses determined at 2 h, 3 h, and
1 day post CBL exposure. Some of the M+CBL animals were treated with
Ondansetron, SB 269970, or a mixture (Mix) prior to nVNS and nociception
measured 1 h and 1 day post treatment. *P < 0.05 when compared to Naïve
while #P < 0.05 compared to M+CBL. +P < 0.05 when compared to M +
CBL + nVNS.

signaling, the GABAA receptor antagonist was administered just
prior to nVNS. All of the animals exhibited a similar level
of nocifensive response to mechanical stimulation at the day
8 time point prior to CBL exposure (Figure 3). As before,
sensitized animals exposed to CBL (n = 13) exhibited elevated
nocifensive responses at 2 h when compared to naïve animals
(n = 14) (M + CBL, P < 0.001; M + CBL + nVNS, P =
0.001; M + CBL + Bic + nVNS, P = 0.003). As expected,
nVNS (n = 14) significantly inhibited (P < 0.05) the level
of nociception mediated by CBL in sensitized animals 1 h
post treatment (P = 0.002). Administration of the GABAA
receptor antagonist Bicuculline (20 µM) prior to nVNS, however,
suppressed the inhibitory effect of nVNS, which resulted in
the average number of nocifensive responses being significantly
different from Naïve levels (n = 7, P = 0.004). However, animals
treated with Bicuculline prior to nVNS were not significantly
elevated compared to animals receiving nVNS alone (P = 0.067).
As a control, Bicuculline administered to sensitized animals
immediately following CBL exposure did not potentiate or inhibit
the nocifensive response and was significantly elevated when
compared to Naïve levels (n = 6, P = 0.001). At day 1 post
treatments, no significant differences in trigeminal nociception
were observed although the trends were similar to the 3 h
time point.
To determine if the inhibitory effect of nVNS on trigeminal
nociception observed in the CBL odor-induced episodic migraine
model also involved activation of 5-HT receptors, selective
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5-HT3 and 5-HT7 antagonists were injected intracisternally
prior to nVNS. All of the animals exhibited a similar level
of nocifensive response to mechanical stimulation at the day
8 time point prior to CBL odor exposure (Figure 4). In this
experiment, all sensitized animals exhibited a robust increase (P
< 0.05) in the average number of nocifensive responses following
pungent odor exposure for each experimental condition.
While nVNS significantly inhibited (P = 0.002) the level
of nociception mediated by CBL odor in sensitized animals
1 h post treatment, administration of the 5-HT3 antagonist
Ondansetron (100 nM) (n = 7), 5-HT7 antagonist SB 269970
(100 nM) (n = 6), or a mixture (100 nM of each) (n = 6),
prior to nVNS suppressed the inhibitory effect of nVNS. The
average number of nocifensive responses for animals treated
with Ondansetron, SB 269970, or the mixture was significantly
different from naïve levels (P = 0.011, P = 0.05, P <
0.001, respectively). Animals treated with Ondansetron or SB
269970 prior to nVNS were not significantly elevated compared
to animals receiving nVNS alone (P = 0.064, P = 0.108,
respectively). However, animals treated with the mixture were
significantly elevated from M + CBL + nVNS animals (P
= 0.007). At day 1 post treatments, no significant differences
in trigeminal nociception were observed when compared to
naïve levels.
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molecular mechanisms. Based on animal studies, the inhibitory
effects of sumatriptan are thought to be primarily mediated via
direct modulation of primary trigeminal neurons and involve
blocking the release of CGRP and the excitatory neurotransmitter
glutamate (12). Hence, sumatriptan’s mechanism of action
would inhibit neurogenic inflammation in the dura, inhibit
neuron-glia communication in the ganglion, and also inhibit
activation of second order neurons and glia cells within the
spinal cord to decrease peripheral and central sensitization of
the trigeminal system. In contrast, the primary effects of nVNS
are likely to be multimodal and would involve modulation
of central cellular activities that regulate descending pain
inhibition pathways (37). The findings from our study provide
evidence for the involvement of GABAA receptors and 5HT3 and 5-HT7 receptors in mediating the inhibitory effect of
nVNS in an episodic migraine model. Specifically, intracisternal
injection of the GABAA receptor antagonist Bicuculline or
administration of the 5-HT7 receptor antagonist SB 269970
and the 5-HT3 receptor antagonist Ondansetron, or a mixture
of the two antagonists, significantly inhibited nVNS repression
of trigeminal nociception. The inhibitory effect of nVNS is
likely to be mediated by activation of GABAA receptors on
primary and second order neurons (32, 38, 39), which would
result in neuronal hyperpolarization via an influx of chloride
to inhibit neurotransmitter release. Although not a focus of
this study, the source of 5-HT is likely from activation of
descending projections from the rostroventromedial medulla
(RVM), which functions as a final relay in the control of
descending pain facilitation. The activation of 5-HT3 and 5HT7 receptors on inhibitory neurons by nVNS would enhance
the descending inhibitory pain pathway via activation of spinal
interneurons and release of the inhibitory neurotransmitters,
GABA and glycine, to suppress ascending pain transmission. This
mechanism is supported by other orofacial pain studies involving
trigeminal nerve activation in which direct stimulation of the
vagus nerve was shown to exhibit anti-nociceptive effects, to
facilitate the serotonergic descending inhibition pathway, and
to modulate inhibition of GABAergic neurons (14, 40, 41).
Other mechanisms may also be involved in nVNS inhibition
of trigeminal pain signaling. In a previous study (23), nVNS
treatment of sensitized animals inhibited CBL odor-stimulated
nuclear expression of the signaling protein P-ERK in trigeminal
ganglia. In the same model of episodic migraine utilized in
this study, nVNS also inhibited stimulated expression of GFAP
and Iba1, which are biomarkers of activated astrocytes and
microglia, respectively (42). These findings are suggestive that
nVNS can inhibit cellular changes implicated in peripheral and
central sensitization. nVNS has also been reported to inhibit the
nitroglycerin-mediated increase in glutamate levels in cerebral
spinal fluid in a model of trigeminal allodynia (24). Another
possible mechanism of nVNS involves the direct regulation
of pain signaling in the upper spinal cord based on data
from a recent human imaging study that provided evidence
of the trigeminal and vagus systems being interconnected at
the level of the spinal trigeminal nucleus (43). Taken together,
the inhibitory effect of nVNS in migraine is facilitated via
multiple mechanisms that function to suppress peripheral

The major finding from our study was that nVNS was as
effective as sumatriptan in inhibiting trigeminal nociception
in two different rodent models of episodic migraine. In both
models, sensitization of trigeminal neurons was mediated by
neck muscle inflammation, which is a reported migraine
risk factor (27, 28). In this primed state, exposure of the
animals to the pungent odor from a CBL extract or a nitric
oxide donor was sufficient to cause a significant transient
increase in trigeminal nociception to mechanical stimulation.
Exposure to either triggering agent in unsensitized animals,
however, did not result in an enhanced state of trigeminal
nociception. In this way, these models are designed to mimic
pathophysiological events associated with episodic migraine in
humans. Importantly, nVNS and sumatriptan were both effective
in inhibiting the increased level of trigeminal nociception
mediated by CBL odor and nitric oxide in sensitized animals.
This finding is consistent with human studies that have
reported nVNS provides a therapeutic benefit that is similar
to that of sumatriptan for the acute treatment of episodic
migraine (11). Our finding that nVNS inhibits the average
number of nocifensive responses to mechanical stimulation
mediated by a pungent odor is also consistent with results
from an earlier study (23) and with results from other animal
studies that mimic aspects of migraine pathology (24, 29, 30)
and other types of orofacial pain (31, 32). While previous
studies have utilized nitric oxide donors to directly cause
trigeminal nociception (24, 33, 34), in our model, a subthreshold
concentration of sodium nitroprusside promoted activation
of trigeminal nocifensive response in sensitized animals. In
this way our model is designed to mimic human studies
in which nitric oxide infusion causes a migraine attack in
migraine susceptible individuals (25). An interesting feature of
our model is that trigeminal nociception is not elevated by
upper trapezius inflammation but rather a sensitized or primed
state of nociceptors is promoted. This pathological condition
mimics a commonly cited risk factor since neck muscle pain
and tenderness are reported during the prodrome and attack
phases of migraine (27, 28). Neck muscle inflammation is
likely to mediate central sensitization of the trigeminal system
via increased peripheral signaling since afferent projections
from these muscles terminate in the upper spinal cord and
subsequently converge with the trigeminal system (22, 35).
This supports the notion that neck muscle inflammation could
promote central sensitization by activating ascending nociceptive
second order neurons or by facilitating downregulation or
dysregulation of the inhibitory descending pain modulation
pathway. These events would result in an increase in the
allostatic load and promote development of a hypersensitive or
hyperexcitable state of the trigeminal system that would be more
responsive to inflammatory stimuli, which is characteristic of
migraine pathophysiology (36).
Although nVNS and sumatriptan are reported to have similar
efficacy in treating episodic migraine, the pathways by which
each of these abortive therapies function to inhibit trigeminal
pain signaling are likely to be mediated via different cellular and

Frontiers in Neurology | www.frontiersin.org

6

March 2020 | Volume 11 | Article 146

Cornelison et al.

nVNS Inhibits Trigeminal Nociception

ETHICS STATEMENT

and central sensitization of the trigeminal system and inhibit
pain signaling.
In summary, exposure to a pungent odor or administration
of nitric oxide, which are both reported migraine triggers in
humans, resulted in an enhanced nocifensive state in response
to mechanical stimulation of trigeminal neurons in animals with
ongoing neck muscle inflammation, another reported risk factor
associated with migraine pathology. nVNS was as effective in
inhibited trigeminal nociception as sumatriptan in two rodent
models of episodic migraine. We propose that the inhibitory
effect of nVNS is mediated, in part, via activation of 5-HT3 and 5HT7 receptors on inhibitory neurons within the spinal trigeminal
nucleus that results in release of GABA and subsequent
activation of GABAA receptors on sensory neurons. However,
5-HT released from the RVM could also directly modulate
sensory neurons via activation of other serotonergic receptors.
Given its central mechanism of action involving GABAergic
and serotonergic pathways associated with descending pain
modulation, nVNS offers a non-pharmacological alternative or
adjunctive therapy to triptans.
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